Follow us on:

Linkedin Facebook

Avacta Group provide clarification regarding Medusa 19 antibody test

lab
[shareaholic app="share_buttons" id_name="post_below_content"]

Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, issues clarification following information appearing on the Medusa 19 web site regarding a SARS-CoV-2 antibody test on Friday, 14 August 2020.

Avacta is not involved with Medusa 19’s development of the antibody test.  Performance figures appearing on Medusa 19’s web site on Friday, 14 August 2020 relate to this antibody test and do not relate to Avacta’s rapid SARS-CoV-2 antigen test.

AVCT will update the market on continued progress and on the performance of its antigen test when appropriate.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

Latest Company News

Avacta Group

Avacta Group notice of results and investor presentation

Avacta Group

Avacta Group Win Diagnostic Licensing Deal with Biokit

Avacta Group plc

Avacta Group MHRA approves Clinical Trial & Excellent data from Lateral Flow Rapid Antigen Test

Avacta

Avacta Group Phase I Clinical Trial Approval by MHRA for AVA6000

Broker Ratings

Market Risers: Avacta Group, Biome Technologies, Cadence Minerals

Avacta Group Excellent data for the first clinical evaluation of lateral flow antigen test (Interview)

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.